The existing evidence points to benefits related to metabolic health, but the supplement may also support different aspects of health, including the following
It was approved by the FDA at the end of 2023
doi: 10.1007/s00018-005-5457-9
3 The takeaway: Behavior change matters to people on GLP-1s, and the Noom app continues to be associated with stronger real-world GLP-1 outcomes Taken together, these findings tell a clear story: people who pair GLP-1 medication with consistent engagement in the Noom app see more success at weight loss, and, independently, they stay with the program longer
Nardin P, Zanotto C, Hansen F, et al
lot-tracked with COA Form: Lyophilized powder available in 5 mg, 10 mg, 30 mg, and 60 mg vials Areas of Research Interest Retatrutide is investigated in the scientific literature in connection with obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD)